Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : AXSM exchanges : Nasdaq save search
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
Published: 2024-04-15 (Crawled : 11:00) - globenewswire.com
AXSM | $74.175 4.32% 300K
|
Health Technology
|
| O: -3.37%
H: 0.83%
C: -0.76%
neurology meeting therapeutics
Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6
Published: 2024-04-10 (Crawled : 11:00) - globenewswire.com
AXSM | $74.175 4.32% 300K
|
Health Technology
|
| O: -2.66%
H: 1.26%
C: 0.37%
first report therapeutics financial results
Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder
Published: 2024-04-01 (Crawled : 11:00) - globenewswire.com
AXSM | $74.175 4.32% 300K
|
Health Technology
|
| O: 0.32%
H: 0.0%
C: -3.52%
treatment trial therapeutics solriamfetol
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
Published: 2024-03-25 (Crawled : 11:00) - globenewswire.com
AXSM | $74.175 4.32% 300K
|
Health Technology
|
| O: 3.64%
H: 0.35%
C: -7.48%
axs-12 narcolepsy symphony trial therapeutics
Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
Published: 2024-03-25 (Crawled : 11:00) - globenewswire.com
AXSM | $74.175 4.32% 300K
|
Health Technology
|
| O: 3.64%
H: 0.35%
C: -7.48%
narcolepsy therapeutics results
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder
Published: 2024-03-19 (Crawled : 11:00) - globenewswire.com
AXSM | $74.175 4.32% 300K
|
Health Technology
|
| O: 0.84%
H: 5.95%
C: 5.09%
treatment trial therapeutics solriamfetol
Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference
Published: 2024-03-05 (Crawled : 12:00) - globenewswire.com
AXSM | $74.175 4.32% 300K
|
Health Technology
|
| O: -0.45%
H: 0.86%
C: -1.58%
conference biopharma global therapeutics
Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
Published: 2024-02-27 (Crawled : 12:00) - globenewswire.com
AXSM | $74.175 4.32% 300K
|
Health Technology
|
| O: 0.75%
H: 2.12%
C: 1.3%
conference therapeutics
Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Published: 2024-02-20 (Crawled : 12:00) - globenewswire.com
AXSM | $74.175 4.32% 300K
|
Health Technology
|
| O: -8.42%
H: 3.52%
C: -4.54%
business year update therapeutics financial results
Axsome Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20
Published: 2024-01-23 (Crawled : 12:00) - globenewswire.com
AXSM | $74.175 4.32% 300K
|
Health Technology
|
| O: 0.62%
H: 0.43%
C: -2.14%
report year therapeutics financial results
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones
Published: 2024-01-04 (Crawled : 12:00) - globenewswire.com
AXSM | $74.175 4.32% 300K
|
Health Technology
|
| O: 2.6%
H: 9.85%
C: 5.02%
year revenue therapeutics
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Dollar General Corporation Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - DG
Published: 2023-12-25 (Crawled : 16:00) - prnewswire.com
BCS | $9.66 1.47% 12M
|
Finance
| Email alert
Add to watchlist
AXSM | $74.175 4.32% 300K
|
Health Technology
| Email alert
Add to watchlist
BCLYF | $2.3 46K
|
Finance
| Email alert
Add to watchlist
DG 4 | $143.48 0.44% 500K
|
Retail Trade
| Email alert
Add to watchlist
corporation deadline global
Autism Spectrum Disorder Therapeutics Market to Grow at a Substantial Growth Rate During the Study Period (2019-2032), Assesses DelveInsight | Key Players in the Market - Otsuka, Jazz, MapLight, Vanda, ACADIA, AbbVie, Axial, Roche, Yamo
Published: 2023-12-19 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: -0.39%
H: 1.49%
C: 0.32%
SUPN | $30.04 1.11% 45K
|
Health Technology
|
| O: -0.11%
H: 0.82%
C: -2.31%
SNY | News | $47.5 0.74% 450K
|
Health Technology
|
| O: 0.21%
H: 0.0%
C: 0.0%
AXSM | $74.175 4.32% 300K
|
Health Technology
|
| O: -0.46%
H: 0.0%
C: -4.03%
ACAD | News | $16.83 -0.94% 520K
|
Health Technology
|
| O: -0.17%
H: 0.76%
C: -3.42%
therapeutics growth study market
Axsome Therapeutics Presents New Data and Post-Hoc Analyses of Auvelity® in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2023 Annual Meeting
Published: 2023-12-11 (Crawled : 12:00) - globenewswire.com
AXSM | $74.175 4.32% 300K
|
Health Technology
|
| O: -0.26%
H: 0.24%
C: -0.5%
auvelity meeting therapeutics
Axsome Therapeutics Hosts Solriamfetol Virtual Investor Event with Expert Thought Leaders Today
Published: 2023-12-07 (Crawled : 12:00) - globenewswire.com
AXSM | $74.175 4.32% 300K
|
Health Technology
|
| O: 0.84%
H: 3.89%
C: 0.43%
therapeutics solriamfetol today
GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Barclays PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - BCS, BCLYF
Published: 2023-11-27 (Crawled : 01:00) - prnewswire.com
BCLYF | $2.3 46K
|
Finance
|
| O: 0.0%
H: 0.28%
C: -1.97%
BCS | $9.66 1.47% 12M
|
Finance
|
| O: -0.69%
H: 0.42%
C: -0.42%
AXSM | $74.175 4.32% 300K
|
Health Technology
|
| O: 0.1%
H: 5.89%
C: 5.83%
AHCO | $9.98 3.96% 220K
|
Finance
|
| O: 0.35%
H: 2.37%
C: 1.16%
deadline
AXSM FINAL DEADLINE NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action - AXSM
Published: 2023-11-26 (Crawled : 00:00) - prnewswire.com
SLRN | $4.75 -1.45% 1.6M
|
|
| O: 0.0%
H: 1.37%
C: -0.46%
AXSM | $74.175 4.32% 300K
|
Health Technology
|
| O: 0.1%
H: 5.89%
C: 5.83%
AHCO | $9.98 3.96% 220K
|
Finance
|
| O: 0.35%
H: 2.37%
C: 1.16%
trusted deadline
Axsome Therapeutics to Host Solriamfetol Virtual Investor Event on December 7
Published: 2023-11-22 (Crawled : 12:00) - globenewswire.com
AXSM | $74.175 4.32% 300K
|
Health Technology
|
| O: 0.37%
H: 2.16%
C: 1.18%
therapeutics solriamfetol
Axsome Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference
Published: 2023-11-21 (Crawled : 12:00) - globenewswire.com
AXSM | $74.175 4.32% 300K
|
Health Technology
|
| O: -1.42%
H: 1.79%
C: -0.02%
conference therapeutics
Axsome Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
Published: 2023-11-06 (Crawled : 12:00) - globenewswire.com
AXSM | $74.175 4.32% 300K
|
Health Technology
|
| O: -4.67%
H: 10.55%
C: 0.52%
business update therapeutics financial results
Gainers vs Losers
| 87% | 13% |
Top 10 Gainers
MTTR | News M | $4.595 164.08% 13M
|
AGBA | $2.61 108.8% 41M
|
Finance
CZOO | $9.32 86.77% 18M
|
EDBL | News | $6.7 78.19% 1.7M
|
MTC | $2.28 46.15% 2.6M
|
Technology Services
OPRT | News | $3.14 39.56% 7.6M
|
Finance
VNRX | $0.8 33.33% 2.9M
|
Health Technology
MLEC | $1.865 33.21% 2.4M
|
n/a
PALI | $6.37 29.21% 21M
|
Manufacturing
LOCL | $3.33 27.59% 43K
|
Your saved searches
Save your searches and get alerts when important news are released.